Back

Potential Lives Saved Through Widespread Global Availability of GLP-1 Receptor Agonists: A Modeling Study

Brook, D.; Singer, P. A.

2024-11-11 public and global health
10.1101/2024.11.11.24317112 medRxiv
Show abstract

This model attempts to quantify the potential impact of GLP-1 receptor agonists (GLP-1) in reducing global mortality linked to obesity, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Using global population data, T2DM and obesity prevalence, cardiovascular risk, and mortality reduction from GLP-1s, we estimate that between ~2.1 million (for people with T2DM or obesity with CVD) and ~3.1 million (for people with T2DM or obesity with/without CVD) lives could be saved annually with widespread global access to GLP-1 receptor agonists.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.